This may be because the non-smoking or light smoking patients with PD-L1-positive tumors had highly immunogenic tumors [25], which indicated that a strong adaptive immune response may attack the tumor microenvironment and ultimately influence the favorable clinical outcomes of patients [11, 23]. This evidence concerns the gene CD274 and neoplasm.